Last updated: February 26, 2026
What is the drug NDC 00480-0126?
The drug identified by NDC 00480-0126 is Samsca (tolvaptan). It is a vasopressin receptor antagonist approved for treating hyponatremia associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH) and conditions like heart failure.
Market Overview
Therapeutic landscape
Tolvaptan competes in the hyponatremia treatment space alongside options like hypertonic saline and other vasopressin receptor antagonists. Its unique mechanism targets aquaporin channels, offering a targeted treatment for complex cases.
Current market size
The global market for hyponatremia drugs was valued at approximately $600 million in 2022. Beijing-based Otsuka Pharmaceutical, the manufacturer, accounts for a majority of sales. The drug's sales are driven by the prevalence of SIADH and heart failure, which affect millions worldwide.
Market growth drivers
- Increasing prevalence of heart failure and SIADH.
- Growing awareness and diagnosis of hyponatremia.
- Expanded approvals for off-label uses such as autosomal dominant polycystic kidney disease (ADPKD).
Competitors
| Drug Name |
Indication |
Market Share |
Annual Sales (2022) |
Approval Status |
| Tolvaptan (Samsca) |
SIADH, ADPKD |
65% |
$350 million |
FDA-approved, off-label uses |
| Conivaptan |
Hyponatremia |
20% |
$100 million |
FDA-approved |
| Hypertonic saline |
Hyponatremia |
10% |
N/A |
Off-label use |
Regulatory landscape
The FDA approved Samsca in 2009. Off-label uses are common but limited by guidelines and safety concerns such as hepatotoxicity. Patent expiration is imminent, with a primary patent expiring in 2027.
Price Analysis
Current pricing
| Region |
Typical Wholesale Price (WAC) for 30-day supply |
Notes |
| US |
$4,500 – $6,000 |
Based on dose and pharmacy setting |
| Europe |
€4,000 – €5,500 |
Similar to US, varies by country |
| Canada |
CAD 6,000 – CAD 8,200 |
Slightly lower than US |
Pricing trends
- Price stability over the past five years.
- Slight reductions in wholesale prices for generics expected post-patent expiry.
- Insurance coverage in the US limits out-of-pocket costs but varies regionally.
Price projections (2023–2028)
| Year |
Expected Price Range (30-day supply) |
Rationale |
| 2023 |
$4,500 – $6,000 |
Stable, no patent expiration or generic competition yet |
| 2024 |
$4,350 – $5,850 |
Slight downward pressure from increasing utilization and generic entry |
| 2025 |
$3,900 – $5,200 |
Entry of generic formulations if patent expires as scheduled |
| 2026 |
$3,500 – $4,800 |
Greater generic market penetration |
| 2027 |
$3,200 – $4,200 |
Increased generic competition; patent expiry expected |
| 2028 |
$2,800 – $3,700 |
Post-patent, generic options dominate, driving prices down significantly |
Cost-effectiveness considerations
Cost-effectiveness analyses favor tolvaptan in select cases due to its targeted mechanism, despite higher prices relative to traditional therapies. Payers are scrutinizing its use based on the severity of hyponatremia and clinical benefits.
Market Entry and Expansion Opportunities
- New indications: Expanding to treat autosomal dominant polycystic kidney disease (FDA approved in 2018) can enlarge market share.
- Biologics and biosimilars: Limited potential, as targeted small molecules dominate.
- Market penetration strategies: Emphasize prescription in complex cases where other treatments underperform.
Risks and Limitations
- Safety profile concerns, especially hepatotoxicity, may limit broader use.
- Patent expiration reduces pricing power.
- Off-label use complications and regulatory restrictions.
Key Market Dynamics Summary
| Aspect |
Details |
| Size |
~$600 million (global, 2022) |
| Growth |
~3–5% CAGR projected for the next five years |
| Competition |
Conivaptan, hypertonic saline, generics post-2027 |
| Patent expiry |
2027 with generic entry likely to reduce prices |
Key Takeaways
- NDC 00480-0126 (Samsca) has a mature market with stable pricing, expected to decline post-2027 due to patent expiry.
- The current global market size is approximately $600 million, with a modest growth rate driven by increasing prevalence of hyponatremic conditions.
- Price projections forecast a 25–35% decline over five years following patent expiry, aligning with historical trends post-generic entry in similar drugs.
- There are opportunities for expansion into additional indications, notably polycystic kidney disease.
- The regulatory environment and safety profile influence market dynamics and pricing strategies.
FAQs
1. How does the patent status affect the price of NDC 00480-0126?
Patent expiry in 2027 will likely lead to generic entries, reducing prices by 25–35% over subsequent years.
2. Are there significant off-label uses influencing the market?
Yes, tolvaptan is used off-label for conditions like autosomal dominant polycystic kidney disease, expanding its market.
3. How competitive is Samsca compared to other hyponatremia treatments?
It holds a dominant share (around 65%) but faces competition from off-label and alternative therapies, with prospects of generic competition reducing its market dominance.
4. What are the primary cost-effectiveness considerations?
While expensive upfront, benefits in complex cases justify costs; payers scrutinize its use based on clinical necessity.
5. What is the potential impact of biosimilars?
Biosimilars are unlikely due to the small molecule nature of tolvaptan, but generic small molecules post-2027 will impact market pricing.
Sources
[1] Otsuka Pharmaceutical. (2022). Samsca (tolvaptan) prescribing information.
[2] IQVIA. (2022). US Pharmaceutical Market Reports.
[3] FDA. (2018). Approval of tolvaptan for ADPKD indications.
[4] MarketWatch. (2022). Hyponatremia drugs market analysis.
